Last updated: 2026-09-09 04:52:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Nurix Therapeutics, Inc. (NRIX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.12, with a market capitalization of $2.71B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.20 to $28.23. This page covers its latest market performance, valuation, price trends and company information.
$2.71B | |
$25.42 | |
$52.38 | |
$4.22 | |
$26.14 | |
1.13M | |
2.01M | |
-- | |
$28.23 | |
$8.20 | |
-- | |
-- |
Nurix Therapeutics, Inc. (NRIX) last closed at $26.14 as of 2026-09-08 23:31:00, unchanged from the previous close of $26.14.
During the latest regular trading session, NRIX traded between $4.22 and $52.38, with a volume of 1.13M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Nurix Therapeutics, Inc. (NRIX) moved from $26.88 to $26.12, representing a decline of 2.80% ($0.75).
The stock traded between $24.01 and $28.02 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 89.5%
NRIX is currently trading at $26.12, placing it 89.5% of the way from its 52-week low of $8.20 to its 52-week high of $28.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 357 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nurix Therapeutics, Inc. (NRIX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.